BioCentury | Sep 27, 2019
Finance

Via Munich office, Kurma launches oncology company Tacalyx

...Inc. (Tokyo:4502), and a onetime CSO of German autoimmune disease company SuppreMol GmbH. Neubeck named globohexaosylceramide (globo-H)...
BioCentury | Mar 13, 2019
Distillery Therapeutics

Inhibiting B3GALT5 or its biosynthetic products for breast and pancreatic cancers

...cell culture and mouse studies suggest inhibiting B3GALT5 or its downstream biosynthetic products SSEA-4 and globo-H...
...breast cancer and a xenograft mouse model of pancreatic cancer, an anti-SSEA-4 mAb or an anti-globo-H...
...anti-B3GALT5 mAbs in mouse models of breast and pancreatic cancer. TARGET/MARKER/PATHWAY: Stage-specific embryonic antigen-4 (SSEA-4); globohexaosylceramide (globo-H)...
BioCentury | Jul 21, 2017
Company News

OBI gains ThioBridge linker tech from Abzena for OBI-999 and other ADCs

...million) in development, regulatory and commercialization milestones, plus royalties. OBI-999 is an antibody-drug conjugate against globohexaosylceramide (globo-H)...
...plc (LSE:ABZA), Babraham, U.K. OBI Pharma Inc. (TPEx:4174), Taipei, Taiwan Business: Cancer Shannon Lehnbeuter OBI-999 Abzena plc OBI Pharma Inc. globo-H SSEA-3 SSEA-4...
BioCentury | Feb 29, 2016
Clinical News

OBI-822/821: Phase II/III data

Top-line data from a double-blind, international Phase II/III trial in 349 treatment-experienced patients with histologically or cytologically confirmed metastatic breast cancer showed that OBI-822/821 plus low-dose cyclophosphamide missed the primary endpoint of improving PFS vs....
BioCentury | Feb 23, 2016
Clinical News

OBI breast cancer therapy misses Phase II/III endpoint

OBI Pharma Inc. (TPEx:4174) said OBI-822/821 missed the primary endpoint of progression free survival (PFS) in a top-line analysis of its Phase II/III study to treat metastatic breast cancer. The company said the data showed...
BioCentury | Dec 18, 2014
Distillery Therapeutics

Therapeutics: Globohexaosylceramide (globo-H); stage-specific embryonic antigen-3 (SSEA-3); SSEA-4

...as antigens for the development of cancer vaccines. Chemical synthesis identified a series of modified globo-H...
...tumor-associated carbohydrate antigens globo-H, SSEA-3 and SSEA4. In mice, vaccination with lead carbohydrate conjugates induced anti-globo-H...
...Next steps could include testing vaccines that use the conjugates in mouse tumor models. TARGET/MARKER/PATHWAY: Globohexaosylceramide (globo-H)...
BioCentury | Mar 11, 2013
Regulation

Dissecting Kadcyla

...inhibitor Ph III OBI Pharma Inc. subsidiary of Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) OPT-822/821 Carbohydrate antigen globo-H...
BioCentury | Oct 15, 2012
Company News

Optimer Pharmaceuticals Inc. Inc. cancer news

...from Optimer to the product, which is a combination of an adjuvant with carbohydrate antigen globo-H...
BioCentury | Oct 9, 2012
Company News

Optimer selling stake in Taiwan subsidiary for $60M

...from Optimer to the product, which is a combination of an adjuvant with carbohydrate antigen globo-H...
BioCentury | Jul 9, 2009
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer; prostate cancer Globohexaosylceramide (globo-H); ganglioside...
...a cancer vaccine. The vaccine was produced by conjugating five breast and prostate cancer-associated carbohydrate antigens-globo-H...
Items per page:
1 - 10 of 14